Triflupromazine (original) (raw)
From Wikipedia, the free encyclopedia
Typical antipsychotic medication
Pharmaceutical compound
Triflupromazine
 |
|
|---|---|
 |
|
| Clinical data | |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a600010 |
| ATC code | N05AA05 (WHO) |
| Legal status | |
| Legal status | US: ℞-only |
| Identifiers | |
| IUPAC name N,_N_-dimethyl-3-[2-(trifluoromethyl)-10_H_-phenothiazin-10-yl]propan-1-amine | |
| CAS Number | 146-54-3  Y |
| PubChem CID | 5568 |
| IUPHAR/BPS | 4330 |
| DrugBank | DB00508  N |
| ChemSpider | 5367 N |
| UNII | RO16TQF95Y |
| KEGG | D00390 N |
| ChEBI | CHEBI:9711 N |
| ChEMBL | ChEMBL570 N |
| CompTox Dashboard (EPA) | DTXSID9023704  |
| ECHA InfoCard | 100.005.158 |
| Chemical and physical data | |
| Formula | C18H19F3N2S |
| Molar mass | 352.42 g·mol−1 |
| 3D model (JSmol) | Interactive image |
| SMILES CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F | |
| InChI InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3 NKey:XSCGXQMFQXDFCW-UHFFFAOYSA-N N |
|
| NY (what is this?) (verify) |
Triflupromazine (Vesprin) is an antipsychotic medication of the phenothiazine class. Among different effects of triflupromazine indication for use of this drug is severe emesis and severe hiccups.[1][2] Due to its potential side effects (triflupromazine has higher risk for side effects than many other antipsychotics) it is not gold standard in antiemetic therapy.
Serious side effects of triflupromazine can be akathisia and tardive dyskinesia as well as the rare, but potentially fatal, neuroleptic malignant syndrome.
It has also been reported to target tubulin, blocking its polymerization.[3]
- ^ Thiele R (September 1965). "[Triflupromazine as a tranquilizer and antiemetic drug in internal medicine]". Medizinische Klinik (in German). 60 (37): 1503–4. PMID 5862106.
- ^ "Triflupromazine". DrugBank.[_dead link_]
- ^ Baksheeva VE, La Rocca R, Allegro D, Derviaux C, Pasquier E, Roche P, Morelli X, Devred F, Golovin AV, Tsvetkov PO (2025). "NanoDSF Screening for Anti-tubulin Agents Uncovers New Structure–Activity Insights". Journal of Medicinal Chemistry. 68 (16): 17485–17498. doi:10.1021/acs.jmedchem.5c01008. PMC 12406199. PMID 40815226.